Differentiation induction of human breast cancer cells by arsenite in combination with tetrandrine.

CONCLUSION: The Erk signaling pathway may be crucially involved in the differentiation induction of breast cancer cells in vitro and in vivo. Collectively, our results suggest that the combination can probably serve as promising candidates for the development of novel therapeutic approaches for different types of breast cancer. PMID: 31934280 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research

Related Links:

AbstractPurposeTo evaluate breast cancer (BC) molecular subtypes association with reproductive characteristics and an index of cumulative exposure to endogenous estrogens (EEI) in Mexican women.MethodsWe performed a study of incident cases and population controls in northern Mexico. We included BC cases with tumor molecular classification in their medical records (n = 509), and classified them as HR+/HER2− (ER+ and/or PR+ and HER2−) (n = 289), HER2+ (HR+ or HR−) (n = 117) or triple negative (TN) (n = 103). We matched controls (n = 1030)...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
In this study, we aimed to analyze the relationship between androgen receptor (AR) and EBP1 expression in HER2+ BC. A total of 282 cases (140 cases of HER2+ invasive BC and 142 HER2-negative invasive BC) were included in this study. We performed immunohistochemistry (IHC) to analyze the expression of AR and EBP1; thereafter, we evaluated the relationship between these two biomarkers and estrogen receptor (ER), progesterone receptor (PR), HER2, p53, Ki67 expression, and other clinicopathological parameters. Of the HER2+ cases, 67 (47.9%) showed high expression of EBP1 (EBP1high) and 73 (52.1%) showed low/no expression of EB...
Source: Virchows Archiv - Category: Pathology Source Type: research
Condition:   Breast Neoplasms Intervention:   Drug: DZD3969 Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Primary Breast Cancer Intervention:   Diagnostic Test: SPECT Sponsors:   Tomsk National Research Medical Center of the Russian Academy of Sciences;   Institute of Bioorganic Chemistry, Russian Academy of Sciences;   Uppsala University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Neoplasms Intervention:   Drug: DZD3969 Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Primary Breast Cancer Intervention:   Diagnostic Test: SPECT Sponsors:   Tomsk National Research Medical Center of the Russian Academy of Sciences;   Institute of Bioorganic Chemistry, Russian Academy of Sciences;   Uppsala University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Neoplasms Intervention:   Drug: DZD3969 Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.
Source: Virchows Archiv - Category: Pathology Source Type: research
Conclusion GRPR and integrin αvβ3 expression results are complementary to 18F-FDG PET/CT findings, and are also significantly correlated with hormone receptors associated with aggressive subtypes. These results may pave the way for GRPR and integrin αvβ3 targeted imaging with 68Ga-labeled molecules and systemic radionuclide treatment with 177Lu-labeled compounds.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Conditions:   HER2-positive Breast Cancer;   Chemotherapy Effect;   Circulating Tumor DNA Intervention:   Diagnostic Test: LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark) Sponsor:   Samsung Medical Center Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Research | Study